MP76-10 TRANSURETHRAL ULTRASOUND ABLATION (TULSA) FOR BENIGN PROSTATIC OBSTRUCTION: 12 MONTHS CLINICAL OUTCOMES

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP76-10 TRANSURETHRAL ULTRASOUND ABLATION (TULSA) FOR BENIGN PROSTATIC OBSTRUCTION: 12 MONTHS CLINICAL OUTCOMES Mikael Anttinen, Antti Viitala, Pouya Doerwald, Pietari Mäkelä, Pertti Nurminen, Heikki Pärssinen, Teija Sainio, Ilari Virtanen, Pekka Taimen, Roberto Sequeiros Blanco, and Peter J. Boström Mikael AnttinenMikael Anttinen More articles by this author , Antti ViitalaAntti Viitala More articles by this author , Pouya DoerwaldPouya Doerwald More articles by this author , Pietari MäkeläPietari Mäkelä More articles by this author , Pertti NurminenPertti Nurminen More articles by this author , Heikki PärssinenHeikki Pärssinen More articles by this author , Teija SainioTeija Sainio More articles by this author , Ilari VirtanenIlari Virtanen More articles by this author , Pekka TaimenPekka Taimen More articles by this author , Roberto Sequeiros BlancoRoberto Sequeiros Blanco More articles by this author , and Peter J. BoströmPeter J. Boström More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003350.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: MRI-guided transurethral ultrasound ablation (TULSA) is a novel therapy option for treating lower urinary tract symptoms (LUTS) caused by benign prostatic obstruction (BPO). The combined data set of all 27 patients is reported here with 12-month outcomes available for 21 men. METHODS: Men with LUTS due to BPO, previously scheduled for primary TURP, were enrolled in this prospective, investigator-initiated, single-center, phase 1-2 study (NCT03350529). Quality of life (QoL) questionnaires including EPIC-26, IPSS , IIEF-5 as well as uroflowmetry and PSA were recorded at baseline, 3, 6, 9, 12, 18, 24, and 36 months post-TULSA. MRI was obtained at baseline, 3- and 12-months. Medication use before and after TULSA and adverse events (AEs) in Clavien-Dindo classification were recorded. RESULTS: 27 patients received TULSA, with a median follow-up of 16-mo. At baseline, median [IQR] age was 67 years [64–72], PSA 3 ug/l [2.2–6.5], prostate volume 53 ml [45–66], average flow rate 3.9 ml/s [3.3–7], maximum flow rate 10.5 ml/s [7.7–14], voided volume 210 ml [123–335], and post-void residual 71 ml [39–249]. Median sonication, hospitalization, and catheterization times were 42 min, 24 h, and 16 d, respectively. AEs included one grade 1, seven grade 2, and one grade 3 events, including urinary tract infection, urinary retention, and epididymitis (grade 3), all resolving within three months. 16/27 patients have completed their 12-mo follow-up with 2 men dropping off due to cancer diagnosis. Between baseline and 12 months, median values for measured parameters changed as follows: prostate volume (based on the elliptic formula) reduced from 53 to 32.5 ml, PSA reduced from 3 to 1.45 ug/l, post-void residual volume decreased from 71 to 54 ml, average flow rate increased from 3.9 to 8 ml/s, Qmax increased from 10.3 to 18.45 ml/s, voided volume increased from 210 to 300.8 ml, IPSS score improved from 17 to 4, IPSS QoL score improved from 4 to 1, IIEF-5 improved from 15 to 20.5, EPIC-26 urinary incontinence domain improved from 85.5 to 100, EPIC-26 irritative/obstructive domain improved from 62.5 to 93.5, EPIC-26 bowel domain improved from 87.5 to 97.92, EPIC-26 sexual domain improved from 55.58 to 68.75, and EPIC-26 hormonal domain remained unchanged at 95. Results of uroflowmetry, functional status, and QOL questionnaires all improved at 12 months despite discontinuation of LUTS medication in 23/27 men receiving medication before. CONCLUSIONS: 12-mon outcomes strengthen our previously reported results on the safety and efficacy of TULSA as a promising treatment option for BPO. Source of Funding: Profound Medical © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1094 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mikael Anttinen More articles by this author Antti Viitala More articles by this author Pouya Doerwald More articles by this author Pietari Mäkelä More articles by this author Pertti Nurminen More articles by this author Heikki Pärssinen More articles by this author Teija Sainio More articles by this author Ilari Virtanen More articles by this author Pekka Taimen More articles by this author Roberto Sequeiros Blanco More articles by this author Peter J. Boström More articles by this author Expand All Advertisement PDF downloadLoading ...